Strategies for managing an outsourcing partner

Robust oversight linked to increased efficiency and better communication with outsourcing partners.
The healthcare industry has undergone a transformation over the last few decades, with an uptick in outsourcing shining through as a key trend. The benefits of outsourcing research, development or manufacturing activities are multifold – it can cut R&D costs, increase efficiency across the value chain, and allows companies to benefit from expertise they may lack in-house.
However, engaging an outsourcing partner such as a CRO or CDMO comes with its risks. According to Stephanie Gaulding, Managing Director at Pharmatech Associates, the more hands-off approach a sponsor takes, the higher the risk becomes.
Gaulding led a session on strategies for managing outsourcing partners at CPHI North America this week and emphasised the importance of creating a robust oversight framework.
‘You need to have processes in place to control quality and oversee your outsource activities,’ she told conference attendees.
‘Without these processes you can run the risk of things going awry - not having adequate oversight, not making sure that products are made in accordance with the associated regulations.’
Gaulding recommended defining activities that can be delegated early in the process, and clearly outlining these in contractual documents.
She added that the level of oversight a sponsor retains is a crucial consideration – too little can lead to delays and miscommunication, while micromanagement can result in inefficiencies.
She said: ‘What we ultimately want to do is stay in that middle range, where we have tailored oversight that is tweaked and adjusted per the conditions that you’re dealing with. That’s going to get you to optimal efficiency, that’s going to get to robust communication.’
Gaulding encouraged sponsors to create detailed oversight plans, which includes everything about the scope and nature of the engagement with the outsourcing partner. She noted that gaining familiarity with an outsourcing partner’s internal processes and systems can pay dividends, so that requirements imposed on them are manageable and more likely to result in success.
‘I’d encourage everybody to understand your partner’s processes really well, go into it with an open mind and only make adjustments where you absolutely think there needs to be an adjustment,’ she said. ‘Because you’re going to cause them to trip over themselves trying to remember all these additional requirements.’
Gaulding also advised assessing a partner’s risk points, mitigating these where possible, and enacting a change management plan.
Related News
-
News Merck invests US$1 billion in new USA-based vaccine facility
Merck annouces the opening of a new state-of-the-art vaccine production plant in Durham, North Carolina, USA, in efforts to bring pharmaceutical product development onto home soil in face of new import tariffs. -
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Trump's federal funding shift could stifle biotech innovation
Over a month into the second term of Donald Trump’s presidency and we have already seen some big changes affecting the healthcare industry. -
News Sanofi receives FDA warning over contamination at manufacturing site
The FDA issues a warning letter to Sanofi over contamination violations found at the Framingham biologics facility, in Boston, MA, USA.
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance